|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF-α) participates in the pathophysiology of Behcet's disease (BD) and myelodysplastic syndrome (MDS).
|
29390339 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (TNF)-blocking agents such as Infliximab, Etanercept, and Adalimumab have been reported to have success in patients with BD.
|
29631062 |
2018 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A literature review was performed using MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials for original studies published in English up to October 31, 2009 and that examined the association of the TNF-alpha promoter polymorphisms with Behçet's disease.
|
20470944 |
2010 |
|
Behcet Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among the cytokines related to innate immunity, the levels of IL-1α, IL-1 β, IL-6, IL-12, IL-15 and TNF-α were statistically higher in BD patients than healthy controls.
|
27939191 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the various immunodysfunctions that are found in BD, patients are increased neutrophil motility and superoxide production, as well as elevated production of tumor necrosis factor (TNF)-α and decreased production of interleukin (IL)-10.
|
28693405 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-tumor necrosis factor-α monoclonal antibodies are effective for refractory intestinal Behçet's disease in real-world situations.
|
30872086 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: The following article aims to summarize the currently available efficacy and safety data of anti-TNFα agents in BD.
|
28503960 |
2017 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of TNFA promoter region haplotype in Behçet's Disease.
|
16891799 |
2006 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
|
31228955 |
2019 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data suggest that other HLA (HLA-C, HLA-DR) and HLA-related [MHC Class I chain-related gene A (MIC-A), TNF-α] genes may play a role in BD co-susceptibility or pathogenesis.
|
21059670 |
2011 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.
|
29671190 |
2018 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of tumor necrosis factor-alpha inhibitors, interferon α and anti-interleukin-1 agents was shown in noncontrolled studies of ocular Behçet disease.
|
27662569 |
2017 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
For example, tumor necrosis factor inhibitors are quite successful in the treatment of rheumatoid arthritis (RA), Behçet's disease (BD), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) but not in that of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren's syndrome (SS) and antineutrophil cytoplasmic antibody-associated vasculitis (AAV), conversely, RA shares genetic backgrounds more with SLE, SSc, SS and AAV than BD, AS and PsA.
|
29623390 |
2018 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, association of the other IL-23R polymorphisms could not be estimated owing to the lack of studies.<b>Abbreviations</b>: BD: Behcet's disease; SNP: single nucleotide polymorphism; HLA: human leukocyte antigen; IL: interleukin; OR: odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium; UK: United Kingdom; NOS: Newcastle-Ottawa scale; GWAS: genome-wide association study; TNF-α: tumor necrosis factor-α.
|
31814470 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, increasing data with the tumor necrosis factor inhibitors suggest that these agents may also be acceptable options for the management of refractory vascular BD in daily practice.
|
29665281 |
2019 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, polymorphic analyses of the TNFB gene and Tau-a microsatellite between the HLA-B and TNF genes indicate that the pathogenic gene of BD is not the HLA-B51 gene itself but another gene located around the HLA-B gene.
|
9509902 |
1997 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated genetic polymorphisms of TNF alpha -308 G/A, TNF beta +252 G/A, and TNFR2 196 R/M in 94 Korean BD patients and age- and sex-matched healthy controls to investigate the role of TNF and TNF receptor polymorphisms in BD.
|
12770792 |
2003 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-23 Receptor Gene Polymorphism May Enhance Expression of the IL-23 Receptor, IL-17, TNF-α and IL-6 in Behcet's Disease.
|
26222305 |
2015 |
|
Behcet Syndrome
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Intestinal lesions of BD expressed interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha and interleukin (IL)-12 mRNA, indicating Th1 skewed responses in vivo. mRNA of Txk, a Tec family tyrosine kinase specific to Th1 cells, was expressed in the lesions, suggesting its contribution to the Th1-dominant responses.
|
15654837 |
2005 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long-term use of tumor necrosis factor inhibitors for the treatment of especially eye disease in Behçet syndrome seems to be safe and efficacious.
|
31609785 |
2020 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIC-A, TNF-α genes) identified as associated to BD because of their LD with HLA-B*51.
|
30252881 |
2018 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behçet's disease.
|
7591872 |
1995 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
New uncontrolled data suggest beneficial effects of anti-TNFs for refractory extra-ocular complications of BS such as pulmonary artery, gastrointestinal and central nervous system involvement.
|
27791958 |
2017 |
|
Behcet Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nine BD patients (mean age 34.55 ± 16.30 years) refractory to tumor necrosis factor blockers and standardized therapies are reported in our survey.
|
24305945 |
2015 |
|
Behcet Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
No apparent differences in interleukin (IL)-4, 6, 8 and 10 were observed, whereas production of soluble IL-2-receptor and tumor necrosis factor (TNF)-alpha were more pronounced in the BD group.
|
21816027 |
2011 |